Free shipping on all orders over $ 500

Talacotuzumab-MMAE

Cat. No. M59303

All AbMole products are for research use only, cannot be used for human consumption.

Talacotuzumab-MMAE Structure
Size Price Availability Quantity
100ug USD 276 In stock
1mg USD 940 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
  • Purity: >95%, Endotoxin < 1 EU/µg
  • COA
  • MSDS
Biological Activity

Talacotuzumab-MMAE is an antibody-drug conjugate (ADC) targeting IL-3Ra / CD123. Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody.

Immobilized human IL 3RA at 2 ug/mL can bind Talacotuzumab-MMAE, the EC50 is 0.1648 ug/mL.

Subtype IgG1
Molecular weight 145 kDa
Endotoxin <1 EU/mg

Chemical Information
Form Solution
Solubility (25°C) For powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml.
Storage Store at ≤ -20℃ for 24 months. Avoid repeated freeze-thaw cycles.
Related Antibody-Drug Conjugates (ADCs) Products
Enfortumab vedotin-ejfv

Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate (ADC) for the management of urothelial carcinoma. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE via a protease-cleavable maleimidocaproylvaline-citrulline linker.

Vandortuzumab vedotin

Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug-conjugate to target prostate cancer.

Farletuzumab MMAE

Farletuzumab MMAE is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab conjugated to MMAE.

Zilovertamab vedotin

Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–drug conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer.

Tisotumab Vedotin

Tisotumab Vedotin is a tissue factor-directed antibody-drug conjugate (ADC) containing a tissue factor-specific fully human monoclonal antibody (TF-011) conjugated to monomethylmethane auristatin E (MMAE), which can be used in studies related to cervical cancer.

  Catalog
Abmole Inhibitor Catalog




Keywords: Talacotuzumab-MMAE supplier, Antibody-Drug Conjugates (ADCs), inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.